Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Han, Weiping; Hölscher, Christian; Li, Yuan; Yang, Weiren; Wang, Xiaohui; Wu, Mei‐Na; Qi, Jin-Shun

doi:10.1016/j.neurobiolaging.2012.04.009

Cited by 118 publications

(97 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment also prevents memory impairments, synapse loss, and the deterioration of synaptic plasticity in the hippocampus (Gault and Holscher, 2008a;McClean et al, 2010;McClean and Holscher, 2014a). Furthermore, in an AD rat model induced by the intrahippocampal injection of Aβ, liraglutide (Han et al, 2013) and Val(8)GLP-1 (Wang et al, 2010 activate cAMP signaling in the brain and protect rats against the Aβ-induced impairments of spatial memory and deficit of LTP in a dose-dependent manner. In the rodent model of sporadic AD by intracerebroventricular injection with streptozotocin (STZ), liraglutide (Xiong et al, 2013), (Chen et al, 2012), Val(8)GLP-1 (Li et al, 2012a), and geniposide (Gao et al, 2014) decrease the hyperphosphorylation of τ and neurofilament proteins.…”

Section: Effects Of Glp-1 On Neurodegenerative Diseasementioning

confidence: 99%

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Hölscher

2016

Reviews in the Neurosciences

Self Cite

View full text Add to dashboard Cite

AbstractIncretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new class of antidiabetic agents for the treatment of type 2 diabetes mellitus (T2DM). Recently, the links between neurodegenerative diseases and T2DM have been identified in a number of studies, which suggested that shared mechanisms, such as insulin dysregulation or IR, may underlie these conditions. Therefore, the effects of incretins in neurodegenerative diseases have been extensively investigated. Protease-resistant long-lasting GLP-1 mimetics such as lixisenatide, liraglutide, and exenatide not only have demonstrated promising effects for treating neurodegenerative diseases in preclinical studies but also have shown first positive results in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients in clinical trials. Furthermore, the effects of other related incretin-based therapies such as GIP agonists, dipeptidyl peptidase-IV (DPP-IV) inhibitors, oxyntomodulin (OXM), dual GLP-1/GIP, and triple GLP-1/GIP/glucagon receptor agonists on neurodegenerative diseases have been tested in preclinical studies. Incretin-based therapies are a promising approach for treating neurodegenerative diseases.

show abstract

Section: Effects Of Glp-1 On Neurodegenerative Diseasementioning

confidence: 99%

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Hölscher

2016

Reviews in the Neurosciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…High-frequency stimulation (HFS) was applied to induce L-LTP of fEPSP. The HFS consisted of 3 series with a 5 min interval, each series containing 3 trains of 20 stimuli with an inter-stimulus interval of 5 ms (200 Hz) and an inter-train interval of 30 s, as described in our previous studies (Han et al, 2013;Qiao et al, 2014). After 3 series of HFS, fEPSPs were recorded at 0.033 Hz for at least 3 h. The amplitude of fEPSPs was normalized to basal fEPSPs and averaged.…”

Section: In Vivo Hippocampal L-ltp Recordingmentioning

confidence: 99%

Leptin attenuates the detrimental effects of β-amyloid on spatial memory and hippocampal later-phase long term potentiation in rats

Tong

Zhang

Hao

et al. 2015

Hormones and Behavior

Self Cite

View full text Add to dashboard Cite

“…Additionally, the GLP-1 analog liraglutide was shown to prevent hippocampal synaptic loss and plasticity (Figure 1), and memory impairment in the APP/PS1 mouse model of AD (121). Recently, other authors reported that liraglutide hampered Aβ plaque formation (122) (Figure 1), reduced astrocyte- and microglia-mediated inflammatory responses (123), and promoted neurogenesis (Figure 1) and neuronal proliferation in dentate gyrus (124). Although these results point toward the beneficial use of liraglutide as an anti-AD pharmacological approach, further clarifying research is needed, with a particular emphasis on the ongoing clinical trials (“Identifying potential effects of liraglutide on degenerative changes” – ClinicalTrials.gov Identifier: NCT01469351; and “Evaluating liraglutide in Alzheimer’s disease” – ClinicalTrials.gov Identifier: NCT01843075).…”

Section: Introductionmentioning

confidence: 98%

Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease â€“ How Anti-Diabetics Could be a Solution for Dementia

Sebastião¹,

Candeias

Santos

et al. 2014

Front. Endocrinol.

View full text Add to dashboard Cite

Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health issues nowadays. T2D is an ever increasing epidemic, affecting millions of elderly people worldwide, with major repercussions in the patients’ daily life. This is mostly due to its chronic complications that may affect brain and constitutes a risk factor for AD. T2D principal hallmark is insulin resistance which also occurs in AD, rendering both pathologies more than mere unrelated diseases. This hypothesis has been reinforced in the recent years, with a high number of studies highlighting the existence of several common molecular links. As such, it is not surprising that AD has been considered as the “type 3 diabetes” or a “brain-specific T2D,” supporting the idea that a beneficial therapeutic strategy against T2D might be also beneficial against AD. Herewith, we aim to review some of the recent developments on the common features between T2D and AD, namely on insulin signaling and its participation in the regulation of amyloid β (Aβ) plaque and neurofibrillary tangle formation (the two major neuropathological hallmarks of AD). We also critically analyze the promising field that some anti-T2D drugs may protect against dementia and AD, with a special emphasis on the novel incretin/glucagon-like peptide-1 receptor agonists.

show abstract

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Cited by 118 publications

References 68 publications

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Leptin attenuates the detrimental effects of β-amyloid on spatial memory and hippocampal later-phase long term potentiation in rats

Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease â€“ How Anti-Diabetics Could be a Solution for Dementia

Contact Info

Product

Resources

About